Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Colorectal Neoplasms|Breast Neoplasms
Interventions: DRUG: Olaparib|DRUG: Cediranib|DRUG: Durvalumab
Sponsor: National Cancer Institute (NCI)